MannKind

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

CEO

Michael E. Castagna

CEOMichael E. Castagna

Employees

407

Employees407

Headquarters

Danbury, Connecticut

HeadquartersDanbury, Connecticut

Founded

1991

Founded1991

Employees

407

Employees407

MNKD Key Statistics

Market cap

1.77B

Market cap1.77B

Price-Earnings ratio

52.70

Price-Earnings ratio52.70

Dividend yield

—

Dividend yield—

Average volume

3.93M

Average volume3.93M

High today

$5.90

High today$5.90

Low today

$5.49

Low today$5.49

Open price

$5.49

Open price$5.49

Volume

5.13M

Volume5.13M

52 Week high

$7.63

52 Week high$7.63

52 Week low

$3.38

52 Week low$3.38

MNKD News

Simply Wall St 2d

How Dr. Ajay Ahuja’s Appointment at MannKind Has Changed Its Investment Story

MannKind Corporation recently appointed Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer, effective September 29, 2025, adding more than 20...

Simply Wall St 2d

Assessing MannKind’s Share Price After FDA Clears Pediatric Use for Afrezza in 2025

If you are watching MannKind right now, you are definitely not alone. The company’s stock has been on quite the journey, stirring up questions about whether it...

TipRanks 4d

Buy Rating for MannKind Supported by Strong Tyvaso Efficacy in IPF Treatment

MannKind, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush maintained a Buy rating on the stock and h...

Analyst ratings

100%

of 8 ratings

Buy

100%

Hold

Sell

More MNKD News

TipRanks 6d

MannKind names Dr. Ajay Ahuja as Chief Medical Officer

MannKind (MNKD) announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective September 29. Dr. Ahuja will report directly to Michael Ca...

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.